NTRB Fundamental Analysis - NUTRIBAND INC

Fundamental Rating

NTRB gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 193 industry peers in the Pharmaceuticals industry. While NTRB seems to be doing ok healthwise, there are quite some concerns on its profitability. NTRB is not priced too expensively while it is growing strongly. Keep and eye on this one!

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year NTRB has reported negative net income.

NTRB had a negative operating cash flow in the past year.

In the past 5 years NTRB always reported negative net income.

NTRB had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -162.11%, NTRB is doing worse than 86.01% of the companies in the same industry.

With a Return On Equity value of -195.43%, NTRB is not doing good in the industry: 66.84% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
ROA	-162.11%
ROE	-195.43%
ROIC	N/A

ROA(3y)-86.9%

ROA(5y)-68.06%

ROE(3y)-100.18%

ROE(5y)-79.11%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

NTRB has a Gross Margin of 34.63%. This is comparable to the rest of the industry: NTRB outperforms 58.03% of its industry peers.

NTRB's Gross Margin has been stable in the last couple of years.

NTRB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	34.63%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-0.68%

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

NTRB does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for NTRB has been increased compared to 1 year ago.

The number of shares outstanding for NTRB has been increased compared to 5 years ago.

The debt/assets ratio for NTRB has been reduced compared to a year ago.

2.2 Solvency

An Altman-Z score of 33.83 indicates that NTRB is not in any danger for bankruptcy at the moment.

Looking at the Altman-Z score, with a value of 33.83, NTRB belongs to the top of the industry, outperforming 95.34% of the companies in the same industry.

NTRB has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.

NTRB has a Debt to Equity ratio (0.01) which is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0.01
Debt/FCF	N/A
Altman-Z	33.83

ROIC/WACCN/A

WACC9.32%

2.3 Liquidity

NTRB has a Current Ratio of 3.71. This indicates that NTRB is financially healthy and has no problem in meeting its short term obligations.

NTRB's Current ratio of 3.71 is fine compared to the rest of the industry. NTRB outperforms 61.14% of its industry peers.

NTRB has a Quick Ratio of 3.47. This indicates that NTRB is financially healthy and has no problem in meeting its short term obligations.

With a decent Quick ratio value of 3.47, NTRB is doing good in the industry, outperforming 61.66% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	3.71
Quick Ratio	3.47

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for NTRB have decreased strongly by -17.68% in the last year.

NTRB shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 18.92%.

NTRB shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 41.99% yearly.

EPS 1Y (TTM)-17.68%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%39.77%

Revenue 1Y (TTM)18.92%

Revenue growth 3Y14.58%

Revenue growth 5Y41.99%

Sales Q2Q%63.39%

3.2 Future

The Earnings Per Share is expected to grow by 100.83% on average over the next years. This is a very strong growth

Based on estimates for the next years, NTRB will show a very strong growth in Revenue. The Revenue will grow by 334.01% on average per year.

EPS Next Y6.67%

EPS Next 2Y110.16%

EPS Next 3Y100.83%

EPS Next 5YN/A

Revenue Next Year528.03%

Revenue Next 2Y557.52%

Revenue Next 3Y334.01%

Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NTRB. In the last year negative earnings were reported.

With a Price/Forward Earnings ratio of 4.79, the valuation of NTRB can be described as very cheap.

NTRB's Price/Forward Earnings ratio is rather cheap when compared to the industry. NTRB is cheaper than 94.82% of the companies in the same industry.

When comparing the Price/Forward Earnings ratio of NTRB to the average of the S&P500 Index (36.42), we can say NTRB is valued rather cheaply.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	4.79

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

NTRB's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.

NTRB's earnings are expected to grow with 100.83% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y110.16%

EPS Next 3Y100.83%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

NTRB does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

NUTRIBAND INC

NASDAQ:NTRB (8/5/2025, 9:55:34 AM)

7.08

-0.03 (-0.42%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)05-30 2025-05-30/amc

Earnings (Next)09-01 2025-09-01

Inst Owners2.9%

Inst Owner Change3.09%

Ins Owners60.16%

Ins Owner Change0%

Market Cap78.94M

Analysts82.86

Price Target15.3 (116.1%)

Short Float %4.09%

Short Ratio1.15

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)-145.1%

Min EPS beat(2)-316.67%

Max EPS beat(2)26.47%

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)0

Avg Revenue beat(2)-6.41%

Min Revenue beat(2)-11.21%

Max Revenue beat(2)-1.6%

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)15.38%

PT rev (3m)15.38%

EPS NQ rev (1m)0%

EPS NQ rev (3m)-6.25%

EPS NY rev (1m)8.2%

EPS NY rev (3m)0%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)-7.24%

Revenue NY rev (1m)0%

Revenue NY rev (3m)-1.6%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	4.79
P/S	32.91
P/FCF	N/A
P/OCF	N/A
P/B	15.47
P/tB	25.16
EV/EBITDA	N/A

EPS(TTM)-0.9

EYN/A

EPS(NY)1.48

Fwd EY20.89%

FCF(TTM)-0.47

FCFYN/A

OCF(TTM)-0.46

OCFYN/A

SpS0.22

BVpS0.46

TBVpS0.28

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-162.11%
ROE	-195.43%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	34.63%
FCFM	N/A

ROA(3y)-86.9%

ROA(5y)-68.06%

ROE(3y)-100.18%

ROE(5y)-79.11%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-0.68%

GM growth 5YN/A

F-Score4

Asset Turnover0.39

Health

		Industry Rank	Sector Rank
Debt/Equity	0.01
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	33.31%
Cap/Sales	3.8%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	3.71
Quick Ratio	3.47
Altman-Z	33.83

F-Score4

WACC9.32%

ROIC/WACCN/A

Cap/Depr(3y)24.77%

Cap/Depr(5y)N/A

Cap/Sales(3y)3.53%

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-17.68%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%39.77%

EPS Next Y6.67%

EPS Next 2Y110.16%

EPS Next 3Y100.83%

EPS Next 5YN/A

Revenue 1Y (TTM)18.92%

Revenue growth 3Y14.58%

Revenue growth 5Y41.99%

Sales Q2Q%63.39%

Revenue Next Year528.03%

Revenue Next 2Y557.52%

Revenue Next 3Y334.01%

Revenue Next 5YN/A

EBIT growth 1Y-8.18%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-72.25%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-71.4%

OCF growth 3YN/A

OCF growth 5YN/A

NUTRIBAND INC (NTRB) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens